140 related articles for article (PubMed ID: 10835683)
1. Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies.
Trojan A; Schultze JL; Witzens M; Vonderheide RH; Ladetto M; Donovan JW; Gribben JG
Nat Med; 2000 Jun; 6(6):667-72. PubMed ID: 10835683
[TBL] [Abstract][Full Text] [Related]
2. Generation of cytotoxic T lymphocytes specific for B-cell acute lymphoblastic leukemia family-shared peptides derived from immunoglobulin heavy chain framework region.
Liu Y; Zhu P; Hu YM
Chin Med J (Engl); 2007 Apr; 120(8):652-7. PubMed ID: 17517179
[TBL] [Abstract][Full Text] [Related]
3. [Proliferation of specific cytotoxic T lymphocytes induced by immunoglobulin heavy chain framework region-derived antigenic nonapeptides].
Liu Y; Zhu P; Hu YM
Zhonghua Yi Xue Za Zhi; 2004 Jan; 84(2):97-102. PubMed ID: 14990121
[TBL] [Abstract][Full Text] [Related]
4. Somatically mutated regions of immunoglobulin on human B-cell lymphomas code for peptides that bind to autologous major histocompatibility complex class I, providing a potential target for cytotoxic T cells.
Gricks CS; Rawlings E; Foroni L; Madrigal JA; Amlot PL
Cancer Res; 2001 Jul; 61(13):5145-52. PubMed ID: 11431353
[TBL] [Abstract][Full Text] [Related]
5. [Function analysis of the family-specific CTL induced by peptides derived from IgHV gene framework region of B-cell malignance].
Guo XL; Zhu P; Liu Y; Liu J; Zhu X
Zhonghua Xue Ye Xue Za Zhi; 2005 Aug; 26(8):453-7. PubMed ID: 16383233
[TBL] [Abstract][Full Text] [Related]
6. Identification of CD19 and CD20 peptides for induction of antigen-specific CTLs against B-cell malignancies.
Bae J; Martinson JA; Klingemann HG
Clin Cancer Res; 2005 Feb; 11(4):1629-38. PubMed ID: 15746068
[TBL] [Abstract][Full Text] [Related]
7. Development of autologous cytotoxic CD4+ T clones in a human model of B-cell non-Hodgkin follicular lymphoma.
Mi JQ; Manches O; Wang J; Perron P; Weisbuch S; Marche PN; Renversez JC; Bensa JC; Sotto JJ; Cahn JY; Leroux D; Bonnefoix T
Br J Haematol; 2006 Nov; 135(3):324-35. PubMed ID: 16984392
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic T cell responses against immunoglobulin in malignant and normal B cells: implications for tumor immunity and autoimmunity.
Gricks CS; Gribben JG
Curr Pharm Des; 2003; 9(23):1889-903. PubMed ID: 12871193
[TBL] [Abstract][Full Text] [Related]
9. [Epitopes recognized by cytotoxic T lymphocytes in immunoglobulin heavy chain variable regions expressed by B-cell acute lymphoblastic leukemia].
Liu Y; Zhu P; Hu YM
Zhonghua Zhong Liu Za Zhi; 2005 Feb; 27(2):106-10. PubMed ID: 15946551
[TBL] [Abstract][Full Text] [Related]
10. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes.
Brossart P; Schneider A; Dill P; Schammann T; Grünebach F; Wirths S; Kanz L; Bühring HJ; Brugger W
Cancer Res; 2001 Sep; 61(18):6846-50. PubMed ID: 11559560
[TBL] [Abstract][Full Text] [Related]
11. Identification and characterization of HLA-class-I-restricted T-cell epitopes in the putative tumor-associated antigens P21-activated serin kinase 2 (PAK2) and cyclin-dependent kinase inhibitor 1A (CDKN1A).
Li G; Hundemer M; Wolfrum S; Ho AD; Goldschmidt H; Witzens-Harig M
Ann Hematol; 2006 Sep; 85(9):583-90. PubMed ID: 16718496
[TBL] [Abstract][Full Text] [Related]
12. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
13. Generation of CA125-specific cytotoxic T lymphocytes in human leukocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Am J Obstet Gynecol; 2009 Jan; 200(1):75.e1-10. PubMed ID: 18976739
[TBL] [Abstract][Full Text] [Related]
14. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
[TBL] [Abstract][Full Text] [Related]
15. [The characteristics of anti-B-cell malignance cytotoxic T lymphocytic clones induced by lymphoma relative peptides].
Guo XL; Zhu P; Zhu X; Liu J; Ou Y; Du JW
Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(21):1476-80. PubMed ID: 16061026
[TBL] [Abstract][Full Text] [Related]
16. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
[TBL] [Abstract][Full Text] [Related]
17. Comparison of various sources of antigen-presenting cells for the generation of GP2-tumor peptide specific cytotoxic T-lymphocytes.
Peiper M; Goedegebuure PS; Alldinger I; Knoefel WT; Izbicki JR; Eberlein TJ
Anticancer Res; 2002; 22(6A):3357-63. PubMed ID: 12530087
[TBL] [Abstract][Full Text] [Related]
18. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M
J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648
[TBL] [Abstract][Full Text] [Related]
19. The TAG family of cancer/testis antigens is widely expressed in a variety of malignancies and gives rise to HLA-A2-restricted epitopes.
Adair SJ; Carr TM; Fink MJ; Slingluff CL; Hogan KT
J Immunother; 2008 Jan; 31(1):7-17. PubMed ID: 18157007
[TBL] [Abstract][Full Text] [Related]
20. Isolation of human lymphocyte antigens class I-restricted cytotoxic T lymphocytes against autologous myeloma cells.
Pellat-Deceunynck C; Jego G; Harousseau JL; Vié H; Bataille R
Clin Cancer Res; 1999 Mar; 5(3):705-9. PubMed ID: 10100725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
